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The hypoxia-inducible factor 1 (HIF-1), in addition to genetic and epigenetic changes, is
largely responsible for alterations in cell metabolism in hypoxic tumor cells. This tran-
scription factor not only favors cell proliferation through the metabolic shift from oxidative
phosphorylation to glycolysis and lactic acid production but also stimulates nutrient supply
by mediating adaptive survival mechanisms. In this study we showed that glycogen syn-
thesis is enhanced in non-cancer and cancer cells when exposed to hypoxia, resulting in
a large increase in glycogen stores. Furthermore, we demonstrated that the mRNA and
protein levels of the ﬁrst enzyme of glycogenesis, phosphoglucomutase1 (PGM1), were
increased in hypoxia. We showed that induction of glycogen storage as well as PGM1
expressionwere dependent on HIF-1 and HIF-2.We established that hypoxia-induced glyco-
gen stores are rapidly mobilized in cells that are starved of glucose. Glycogenolysis allows
these “hypoxia-preconditioned” cells to confront and survive glucose deprivation. In con-
trast normoxic control cells exhibit a high rate of cell death following glucose removal.
These ﬁndings point to the important role of hypoxia and HIF in inducing mechanisms of
rapid adaptation and survival in response to a decrease in oxygen tension.We propose that
a decrease in pO2 acts as an “alarm” that prepares the cells to face subsequent nutrient
depletion and to survive.
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INTRODUCTION
Modiﬁed metabolism is a hallmark of cancer cells. It is now
well known that tumors in general have a high rate of glucose
uptake in parallel to elevated glucose consumption (Semenza,
2010; Brahimi-Horn et al., 2011; Porporato et al., 2011). This high
avidity for glucose coupled to an increase in glycolysis in the pres-
ence of plentiful amounts of oxygen is called the “Warburg effect”
or aerobic glucose metabolism, a common feature of many cancer
cells (VanderHeiden et al., 2009). Internalized glucose is converted
into pyruvate and then into lactic acid. In contrast, in non-cancer
cells pyruvate is transported to the mitochondria, where it enters
the tricarboxylic acid (TCA) cycle and participates in oxidative
phosphorylation. As tumor cells proliferate rapidly they become
distanced from oxygen-carrying blood vessels and are no longer
oxygenated. Thus tumors contain extensive regions of hypoxia, a
deﬁciency in the availability of oxygen, which activates a signaling
cascade driven by the transcription factor hypoxia-inducible fac-
tor (HIF), often referred to as the master regulator in the hypoxic
response of cells (Mazure et al., 2004;Majmundar et al., 2010).HIF
belongs to the large family of basic-helix–loop–helix (bHLH) pro-
teins and is a heterodimer of a constitutively expressed and stable
HIF-1β subunit, and one of three oxygen-regulated HIF-α sub-
units (HIF-1α, HIF-2α, or HIF-3α). HIF activation is a multi-step
process involving HIF-α stabilization, nuclear translocation, het-
erodimerization, transcriptional activation, and interaction with
other proteins (Brahimi-Horn et al., 2007a; Aragones et al., 2009;
Semenza, 2010). One of these proteins, the von Hippel–Lindau
(pVHL) protein, is a component of an E3 ubiquitin ligase com-
plex that negatively regulates the stability of the HIF-α protein and
thus its activity. In clear cell renal carcinoma cells (cRCC) pVHL
loss of function results in constitutive HIF-1 activation and thus
constitutive up-regulation of HIF-target genes in normoxic con-
ditions (Kaelin, 2009). More than a hundred genes are estimated
to be regulated by HIF, in an induced or repressed manner (Man-
alo et al., 2005). Interestingly, the majority of the gene products
involved in glycolysis are up-regulated in hypoxia through HIF-α
stabilization and more speciﬁcally through HIF-1. While fermen-
tative glucose metabolism produces less ATP, cells compensate via
HIF-1 by increasing uptake and consumption of glucose thereby
triggering an increased rate of ATP production along with a high
amount of lactic acid, a process referred to as “the Pasteur effect”
(Gatenby and Gillies, 2004; Brahimi-Horn et al., 2007b; Kroemer
and Pouysségur, 2008).
As energy is the key to cancer cell growth, multiple alter-
native catalytic processes, diverging, or not from the glycolytic
pathway, are induced to fuel cells in all circumstances (Kaelin
and Thompson, 2010). The pentose phosphate pathway (PPP)
or hexose monophosphate shunt contributes to nucleic acid syn-
thesis (Buchakjian and Kornbluth, 2010). This pathway generates
ribose 5-phosphate and nicotinamide adenine dinucleotide phos-
phate (NADPH), which are essential in protecting cells from
reactive oxygen species (ROS). In addition, glutamine enters the
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mitochondria where it is oxidized by the TCA cycle (Shanware
et al., 2011). Some cancer cells cannot survive in the absence
of exogenous glutamine and exhibit “glutamine addiction” (Wise
and Thompson, 2010). Like glucose, glutamine also participates in
nucleotide synthesis by contributing nitrogen for pyrimidine and
purine synthesis. Together with glucose, glutamine can contribute
to the production of non-essential amino acids through pyruvate
transamination. Recent studies suggested that glutamine could be
a key substrate required for anabolic growth of mammalian cells.
Finally, autophagy, an evolutionarily conserved cell survival path-
way, participates in degradation of cytoplasmic constituents and
the recycling of ATP. As such it is essential for maintenance of cel-
lular biosynthesis during nutrient deprivation or metabolic stress
(Chen andKarantza, 2011).We showed recently that hypoxic stress
induces autophagy,which temporarily allows non-cancer and can-
cer cells to survive (Bellot et al., 2009; Mazure and Pouyssegur,
2009). We proposed that hypoxia is an early pro-survival con-
dition, acting as a warning signal for cells to anticipate extreme
nutritional stress (Brahimi-Horn et al., 2011).
The various metabolic adaptation strategies described above
enable tumor cells to survive under drastic environmental condi-
tions including severe hypoxia combinedwith glucose deprivation.
Glycogen storage is emerging as a metabolic survival pathway.
Glycogen, a polymer of glucose residues, that is found in the form
of granules, are visible with an electron microscope in the cyto-
plasm in many cell types (McBride et al., 2009). Glycogen plays
an important role in glucose metabolism and forms an energy
reserve that can be quickly mobilized to meet a sudden need for
energy. It is essentially present in the liver and skeletal muscle.
Vigoda et al. (2003) were the ﬁrst to propose that hypoxia plays
a role in glycogen metabolism in rat heart muscle cell cultures.
However, the authors showed that the glycogen content decreased
by 15% compared to the control after only 2 h of drastic hypoxia
(0.01%O2) in glucose-freemedium. Pescador et al. (2010) showed
that hypoxia (1% O2) resulted in accumulation of glycogen in
mouse myotubes, hepatocytes, and hepatoma cells. These authors
demonstrated that glycogen synthase 1 (GYS1), through HIF-1,
was implicated in hypoxia-induced glycogen metabolism together
with up-regulation of the enzymes UTP: glucose-1-phosphate
uridylyltransferase (UGP2) and 1,4-α glucan branching (GBE1).
Importantly, cells preconditioned in hypoxia were more resistant
to cell death when exposed to anoxia than cells preconditioned
in normoxia. Similar results were obtained by Shen et al. (2010)
in human MCF-7 cells when the cells were exposed to 24 or 48 h
of hypoxia (1% O2). They found that the protein phosphatase 1
regulatory subunit 3C gene (PPP1R3C), also regulated by HIF-
1, activated glycogen synthase, and limited glycogen breakdown
through a reduction in the glycogen phosphorylase activity. These
two actions lead to glycogen accumulation. However, the authors
did not discuss the survival potential of such a mechanism in
cancer cells and did not investigate glycogen accumulation as a
general characteristic of tumor cells. Finally, we established that
RCC cells, in which pVHL is mutated in approximately 50% of
cRCC patients (Kaelin, 2009), showed an enlarged cytoplasm due
to abnormalities in glycogen and sterol storage (Medina Villaamil
et al., 2011). As tumor cells are addicted to glucose and glucose
deprivation occurs in parallel to hypoxia, we hypothesized that the
decrease in the oxygen level sensed by cancer cells signals energy
storage. Thus, hypoxia heralds drastic microenvironmental con-
ditions and gives cells time to respond and survive. We previously
reported the importance of glycolysis, however there exists also
a branched circuit, glycogen synthesis, which can play a role in
energy storage. Glucose taken up by the cell is rapidly modiﬁed
from glucose-6-phosphate (G6P) to glucose-1-phosphate (G1P)
and then to UDP-glucose. UDP-glucose is then incorporated into
glycogen particles through a α1–4 linkage. When a chain of at
least 11 residues is formed, a branching enzyme transfers seven
glucose residues to another chain making 1–6 linkages between
glucose. This process is repeated to form a huge fractal struc-
ture, as described by Whelan’s model (Meléndez et al., 1999). This
reversible process, catalyzed by phosphorylases, can occur in a
very short period of time and thus can become a supplier of a
substantial amount of fuel.
Do cancer cells store glycogen? Does it occur in hypoxia when
glycolysis is already exacerbated? Once accumulated, is glycogen
used as a fuel, to feed into glycolysis? For how long can cells sur-
vive on this energy source? These are the questions we asked in
this study.
MATERIALS AND METHODS
CELL CULTURE
Non-neoplastic Chinese hamster lung ﬁbroblasts CCL39, the
respiratory-deﬁcient CCL39-derived mutants (Res−; Franchi
et al., 1981) and the glycolysis-deﬁcient CCL39-derived mutants
(Gly−) due to a mutation that inactivates the expression of the
phosphoglucose isomerase gene (Pouyssegur et al., 1980), MEF
HIF-1+/+ and −/−, human colon carcinoma LS174, human
breast carcinoma MCF-7 and MDA-MB231, human renal clear
cell carcinoma RCC4 cells were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM; Gibco-BRL) supplemented with 7.5 or
10% inactivated fetal bovine serum (FBS) as appropriate. LS174
cells expressing the tetracycline (Tet) repressor were kindly pro-
vided by van de Wetering et al. (2003). The antibiotics penicillin G
(50U/ml) and streptomycin sulfate (50μg/ml) were added. When
experiments with cells were done with medium containing 5mM
glucose, medium was changed every 24 h to minimize variations
in the glucose concentration in the medium during the time of the
experiment.
A Bug-BoxTM anaerobic work station (Ruskinn Technology
Biotrace International Plc, Bridgend, UK) set at 1 or 0.1% oxygen,
94 or 94.9% nitrogen, and 5% carbon dioxide was used.
GLYCOGEN TITRATION
The titration of glycogen was performed using the Glycogen Assay
Kit (Abcam) according to the manufacturer instructions. Brieﬂy,
cells were harvested and washed two times with PBS to remove
traces of glucose from the culture medium. The cell pellet was
then resuspended in 100μl H20 and 100μl of the lysis buffer pro-
vided with the kit. Samples were then centrifuge 15min 16,000 g
at 4˚C and the supernatant retained. Fifty microliter of the super-
natant was then digested with glucoamylase to obtain the amount
of “total glucose” in the sample; a non-digested sample was used
to obtain the amount of “free glucose.” The glucose generated for
each sample was then oxidized to generate a product that reacts
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with a OxiRed probe to generate ﬂuorescence (Ex 535 nm/Em
587 nm), which was measured by ﬂuorescence spectroscopy, using
a Perkin-Elmer LS-50B luminescence spectrometer (Perkin-Elmer,
Waltham,USA).The glycogen content of the samplewas calculated
by subtracting“free glucose”present in the extract before digestion
and normalized to the protein concentration of the sample.
ELECTRON MICROSCOPY
Cells were ﬁxed in situ with 1.6% glutaraldehyde in 0.1M phos-
phate buffer at room temperature (RT) and stored overnight at
48˚C. Samples were rinsed in the same buffer and then post-
ﬁxed with 1% osmium tetroxide and 1% potassium ferrocyanide
in 0.1M cacodylate buffer for 1 h at RT to enhance the stain-
ing of cytoplasmic membranes. Cells were rinsed with distilled
water, embedded in epoxy resin, sectioned, and examined with a
Philips CM12 transmission electron microscope equipped with an
Olympus SIS CCD camera.
PERIODIC ACID SCHIFF STAINING AND GLYCOGEN DETERMINATION
Coverslips were placed in six-well plates, and CCL39, LS174, and
RCC4 cells added. After incubation and treatment, the medium
was removed and the cells were ﬁxed with Carnoy’s ﬁxative for
1 h. The cells on coverslips were rinsed with absolute alcohol and
66% alcohol once for 2min, followed by rinsing with deionized
water for 90 s (3× 30 s). The cells were treated with periodic acid
solution for 10min and then rinsed with deionized water for 90 s
(3× 30 s). Then the cells were treated with Schiff reagent for 15–
20min and rinsed for 5minwith running tapwater. For visualizing
nuclei, the cells were counterstained usingMayer’s hematoxylin for
1min and washed in running tap water for 5min. After air-drying,
the stained cells were covered with a glass slides using pure glycerol
as mounting medium. For glycogen determination, glycogen was
extracted as previous described by Shen et al. (2010).
RNA EXTRACTION, RT-PCR, AND REAL-TIME QUANTITATIVE PCR
Total RNA was extracted from cells using the RNA extraction
kit (Qiagen) according to the manufacturer’s instructions. Total
cDNA were then obtained using the Quantitect Reverse Transcrip-
tion Kit (Qiagen). Expression levels of pgm1 and rplp0, the latter
was used as control, were analyzed by real-time quantitative PCR
using the Taqman Gene Expression Assays (Applied Biosystems).
IMMUNOBLOT ANALYSIS
Cells were lysed in 1.5× sodium dodecyl sulfate (SDS)-buffer,
and the protein concentration was determined using the bicin-
choninic acid assay. Forty micrograms of each whole-cell extract
was resolved by electrophoresis on SDS-polyacrylamide gels and
transferred onto a polyvinylidene diﬂuoride membrane (Milli-
pore). Membranes were blocked in 5% fat-free milk in TN buffer
(50mM Tris–HCl, pH 7.4, 150mM NaCl) and incubated in the
presence of the primary and then the secondary antibody in 5%
fat-free milk in TN buffer. After washing in TN buffer containing
1% Triton X-100 and then in TN buffer, immunoreactive bands
were visualized with the ECL system (Amersham Biosciences).
The anti-PGM1 antibody (clone 3B8-H4) was purchased from
Sigma. The anti-HIF-2α antibody (NB100–480) was purchased
from Novus Biochemicals. The rabbit polyclonal anti-HIF-1α
(antiserum 2087; Richard et al., 1999) and anti-ARD-1 (Bilton
et al., 2005) antibodies were produced and characterized in our
laboratory.
CELL SURVIVAL ASSAY
Cells were preconditioned in hypoxia (1 or 0.1% O2 for the given
timeperiod stated in ﬁgure legends) prior to glucose removal. Cells
cultured in normoxic conditions were used as a control. With-
drawal of glucose was done after washing cells twice with PBS
by adding DMEM without glucose, without pyruvate (Invitro-
gen) supplemented with 7.5% of dialyzed FBS and 1mM sodium
pyruvate. The rate of mortality was assessed using Trypan blue
exclusion staining (Sigma, St. Louis, MO, USA).
STATISTICS
All values are the means± SD of the indicate number of determi-
nations (n) and signiﬁcant differences are based on the Student’s
t -test and P-values indicated.
RESULTS
HYPOXIA INDUCES GLYCOGEN STORAGE IN NON-CANCER AND
CANCER CELL LINES
We ﬁrst analyzed non-neoplastic (CCL39 and MEF) and tumor
(BE, MCF-7, MDA-MB213, PC3, and RCC4) cell lines. As seen in
Table 1, all the cells tested had detectable levels of glycogen when
Table 1 | Basal level and glycogen accumulation (ng/μg proteins) after 96h of hypoxia in normal (CCL39 and MEF) and cancer (BE, MCF-7,
MDA-MB231, LS174, PC3, RCC4) cells.
Nx or (+)pVHL
(ng/μl proteins)
Hx 1% 96h or (−)pVHL
(ng/μl proteins)
Fold induction
(Hx/Nx)
RCC4 Human renal clear carcinoma cell 247.5±3.5 1184±228.3 4.8
MCF-7 Human breast carcinoma cells 113.9±5.8 680.0±12.6 6
CCL39 Chinese hamster lung ﬁbroblast cells 17.2±11.4 638.7±193.6 37
MEF Mouse embryonic ﬁbroblast cells 10.5±7.7 106.0±18.2 10
MDA-MB231 Human breast carcinoma cells 10.0±2.3 98.0±13.7 (Hx 0.1% – 48h) 9.8
LS174 Human colon carcinoma cells 5.0±4.4 128.0±58.2 25.6
BE Human colon carcinoma cells 3.0±1.0 60.0±6.3 20
PC3 Human prostate carcinoma cells Not detected Not detected
Cells were grouped according to their basal amount of glycogen in normoxia.
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grown in tissue culture, with the exception of human prostate
carcinoma PC3 cells. We grouped these cells according to their
basal amount of glycogen in normoxia. The range of glycogen
concentrations was quite broad (Table 1). Human renal clear cell
carcinoma carcinoma RCC4 cells had a large amount of glycogen
(247.5± 3.5 ng/μg protein). All cells expect PC3 cells, showed an
increase in the amount of glycogen after incubation for 96 h in
hypoxia.
Electron microscopy revealed in numerous cell types, non-
membrane-bound cytoplasmic inclusions composed of densely
packed ﬁne granular material that resembled glycogen as deﬁned
by Ghadially (1989). Particules of glycogen are represented by
either are electron-dense granules of approximately 15–30 nm
diameter (β particles or monoparticulate form) or as collec-
tions of such particules forming rosettes of about 80–100 nm in
diameter. Figure 1A showed that CCL39 and LS174 cells show
intensely stained monoparticulate forms of glycogen in the cyto-
plasm (Figure 1 – white arrows). While electron micrographs of
normoxic non-neoplastic Chinese hamster lung ﬁbroblasts CCL39
and human colon carcinoma LS174 cancer cells did not show
glycogen particles (Figures 1A–C) hypoxic CCL39 cells showed
large areas of electron-dense cores of glycogen particles after
96 h of hypoxia (Figure 1A, left panels) in contrast to hypoxic
LS174 cells that showed ﬁnely dispersed glycogen particles or
small aggregates of glycogen (Figure 1A, right panels). These
observations were conﬁrmed by both Periodic acid Schiff (PAS)
staining and by biochemical titration of the glycogen content of
these cells in normoxia and hypoxia at different times points
(Figures 1B,C). Moreover, as predicted by electron microscopy,
CCL39 cells had more glycogen than LS174 cells. The cell cul-
ture media contained 25mM glucose, a concentration that is not
physiological in blood vessels around normal or tumor cells. So
we measured glycogen accumulation in CCL39 cells in hypoxia
at the same time points and in drastic hypoxia (0.01% O2),
but at the more physiological concentration of 5mM glucose
(Figure 1D). Glycogen accumulation was still observed but to a
lesser extent. Taken together these results indicate that hypoxia
stimulates glycogen formation in both non-cancer and cancer
cells.
HYPOXIA-INDUCED GLYCOGEN ACCUMULATION OCCURS VIA HIF
As HIF is the key regulator of hypoxic adaptation of normal
and cancer cells, we investigated the potential role of HIF in
glycogen accumulation using human renal clear cell carcinoma
RCC4 and 786-O cells that contained constitutively stable HIF-
1α and HIF-2α or HIF-2α only respectively due to a defect in
the tumor suppressor pVHL, which participates in the degrada-
tion of the HIF-α proteins (Figure 2A). We thus examined RCC4
cells in which wild-type VHL was re-introduced. Using electron
microscopy, we observed large aggregates of glycogen particles in
RCC4 (−pVHL) cells under normoxic conditions (Figure 2B).
However, no glycogen was observed in RCC4 (+pVHL) cells,
in which HIF-α was degraded in normoxia. To conﬁrm these
results, we measured glycogen accumulation in RCC4 cells. As
expected, RCC4/786-O (−pVHL) cells showed a high concen-
tration of glycogen compared to RCC4/786-O (+pVHL) cells
(1184± 228.3 ng/μg protein versus 247.5± 3.5 ng/μg protein,
FIGURE 1 | Accumulation of glycogen in hypoxia in non-cancer and
cancer cells. (A) Electron micrographs of CCL39 (left panel), LS174 (top
right panel), and HeLa (bottom right panel) cells in normoxia (Nx – 72 h) and
hypoxia 1% O2 (Hx 1% – 72 or 96 h). Arrows denote aggregates of
glycogen particles in CCL39 and LS174 cells. (B) PAS staining of CCL39 and
LS174 cells exposed to normoxia (Nx) and hypoxia (Hx) for 96 h. (C)
Quantiﬁcation of the amount of glycogen in CCL39 (black bars) and LS174
(white bars) cells grown in normoxia (Nx) or hypoxia 1% O2 (Hx 1%) for 48,
72, and 96 h in a 25-mM glucose-containing medium. (D) Quantiﬁcation of
the amount of glycogen in CCL39 cells grown in normoxia (Nx) and hypoxia
1% O2 (Hx 1%) for 48, 72, or 96 h (black bars) and hypoxia 0.1% O2 (Hx
0.1% – gray bar) in a 5-mM glucose-containing medium. Data represent the
average of at least three independent experiments.
respectively for RCC4 and 34.3 ± 18.5 ng/μg protein versus
1.1± 0.8 ng/μg protein, respectively for 786-O cells (Figure 2C;
Table 1). Finally,weusedLS174Tr cells inwhichhif-1αwas silenced
by tetracycline (Tet)-inducible shRNA expression. Hypoxic LS-
sh hif-1α cells treated with Tet showing a 90% decrease in the
mRNA level of HIF-1α (Chiche et al., 2009) did not accu-
mulate glycogen after 48 h in 0.1% O2 (Figure 2D). These
results demonstrate that hypoxia-induced glycogen accumula-
tion is primarily dependent on HIF-1α in majority but also on
HIF-2α.
PHOSPHOGLUCOMUTASE 1 IS UP-REGULATED IN HYPOXIA
Phosphoglucomutase 1 (PGM1) is the ﬁrst enzyme in glycogenesis
that catalyzes the conversion of glucose-6-phosphate to glucose-
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FIGURE 2 | Accumulation of glycogen in hypoxia is dependent on
HIF-1. (A) RCC4 and 786-O cells in the absence (−pVHL) or presence
(+pVHL) of pVHL were placed in normoxia for 24 h. Total extracts were
analyzed by immunoblotting with antibodies against HIF-1α, HIF-2α, and
β-Actin. (B) Electron micrographs of RCC4 −pVHL (left panel) and RCC4
+pVHL (right panel) cells in normoxia. (C) Quantiﬁcation of the amount of
glycogen in RCC4 −pVHL (white bars) and +pVHL (black bars) cells grown
in normoxia. (D) Quantiﬁcation of the amount of glycogen in LS174
pTerHIF-1α cells grown in normoxia (Nx; white bars) or hypoxia 0.1% O2 (Hx
0.1% – black bars) in the absence (−) or presence (+) of tetracycline (Tet).
Data represent the average of at least three independent experiments.
1-phosphate (Figure 3A). Since we were unable to examine the
mRNA level of PGM1 by qPCR in CCL39 cells, since the Hamster
DNA sequence is not available and mouse primers did not detect
hamster PGM1, we examined the PGM1 mRNA level in LS174,
MCF-7, MDA-MB231 (Figure 3B), and RCC4 cells (Figure 3C).
From 24 to 72 h of hypoxia (Hx 1% O2), the PGM1 mRNA level
increased about fourfold. Induction of PGM1 was HIF-dependent
as a threefold increase was detected in RCC4 (−pVHL) cells com-
pared to RCC4 (+pVHL) cells (Figure 3C) and as a twofold
increase was detected in LSpTerHIF-1α in the absence of Tet
(−Tet) and was not observed in the presence of Tet (+Tet) when
HIF-1α was silenced (Figure 3D). Moreover, PGM1 induction in
hypoxia (Hx 1% O2) was observed in both CCL39 (Figure 3E)
and LS174/MCF-7/MDA-MB231 (Figure 3F) cells at the protein
level. Moreover, in LSpTerHIF-1α, hypoxic induction of PGM1
was not observed in the presence of Tet (+Tet) when HIF-1α was
silenced (Figure 3G). These results indicate that pgm1 is a new
HIF-target gene and suggest that PGM1 could promote the ﬁrst
step of glycogenesis in hypoxia.
GLYCOLYSIS, RESPIRATION, AND GLYCOGENESIS ARE CLOSELY
CONNECTED
To deﬁne a possible interconnection between glycogenesis, glycol-
ysis, and respiration, we examined respiration-defective CCL39
cells (Res−) cells and glycolysis defective CCL39 cells (Gly−), cell
lines derived from wild-type CCL39 (WT) cells (Pouyssegur et al.,
2001). As previously observed (Figure 3D), PGM1 was induced in
hypoxia in WT cells. However, Res−cells, which use mainly gly-
colysis for glucose metabolism and are glucose addicted, showed
a higher amount of PGM1 protein in normoxia compared to WT
cells (Figure 4A). The difference between normoxia and hypoxia
was weak but reproducible in Res− cells. In Gly− cells, which use
only oxidative metabolism and grow slowly, hypoxic induction of
PGM1 was similar to that observed in WT cells. Glycogen accu-
mulation was measured in parallel (Figure 4B). Interestingly, cells
with no respiration (Res−) but a high level of glycolysis and low
hypoxic induction of PGM1 stored less glycogen than cells defec-
tive in glycolysis (Gly−) but dependent on oxidative metabolism
and with strong induction of PGM1. We next investigated how
fast cells consumed glycogen in the absence of glucose after accu-
mulation of glycogen in hypoxia. More than 75% of the glycogen
stored by the WT cells was consumed in 3 h, whereas 90% of the
glycogen was used by Res− cells (Figure 4C). However, Gly− cells
needed more time (8 h) to consume less than 75%.
Taken together, these results show direct and indirect connec-
tions between glycolysis, respiration, and glycogenesis. In Res−
cells, forced glycolysis impacts on basal PGM1 expression but does
not impact on hypoxic induction of PGM1 and glycogen accu-
mulation. However, it signiﬁcantly modiﬁed the rate of glycogen
consumption. While in Gly− cells PGM1 expression and glycogen
storage were comparable to that of WT cells. However, as Gly−
cells do not require more energy as they survived on respiration,
glycogen consumption was lower than that of WT cells.
GLYCOGEN ACCUMULATION IS A SURVIVAL RESPONSE IN
NON-CANCER AND IN MANY CANCER CELL LINES
We then hypothesized that the glycogen stored in hypoxia, is
mobilized through glycogenolysis when cells encounter a low
glucose-containing microenvironment (Figure 3A). Cells were
thus exposed to hypoxia of 1% O2 for 96 h and the glucose was
then removed. Glycogen was measured after removal of glucose
for 1, 3, and 6 h. As the amount of glycogen stored after 96 h of
hypoxia is different for each cell line (Table 1), glycogen degra-
dation was given as a percentage. CCL39 and MCF-7 cells, with
similar amounts of accumulated glycogen (638.7± 193.6 ng/μg
protein and 680± 12.6 ng/μg protein, respectively) also showed
a similar rate of glycogen degradation. After 6 h, the amount of
glycogen decreased by 87.3 and 75%, respectively (Figure 5A).
However, LS174 cells consumed all their glycogen in 6 h when
glucose was removed whereas MDA-MB cells consumed less than
70% of their glycogen. Thus the rate of glycogenolysis was similar
for different cell types when the cells had a comparable amount of
stored glycogen to start with (high glycogen for CCL39 and MCF-
7 cells and low glycogen for LS174 and MDA-MB231; Figure 5A;
Table 1). Finally, we investigated whether glycogen conversion to
glucose-1-phosphate, a derivative of glucose that feeds into gly-
colysis, favors cell survival in hypoxic and no glucose conditions.
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FIGURE 3 | Phosphoglucomutase1 is overexpressed in hypoxia to induce
glycogen production. (A) Formation (glycogenesis) and hydrolysis
(glycogenolysis) of glycogen. Glucose is rapidly transported into the
cytoplasm for transformation into glucose-6-phosphate by hexokinases 1 and
2 (HK). Glucose-6-phosphate is at the junction between glycolysis and
glycogenesis. Phosphoglucomutase 1 (PGM1) is the ﬁrst enzyme in
glycogenesis that catalyzes the conversion of glucose-6-phosphate into
glucose-1-phosphate, then into UDP-glucose. Glycogen synthase 1 (GS1)
ﬁnalizes glycogen synthesis. This process is called glycogenesis. The reverse
process that hydrolyzes glycogen into glucose via glycogen phosphorylase
(GP) and a 1-6 glucosidase (1-6 G) is called the glycogenolysis. (B) Expression
of the mRNA of PGM1 was determined by real-time qPCR in LS174 (black
bars), MCF-7 (gray bars) and MD1-MB231 (white bars) cells in 24-, 48-, and
72-h in normoxia (Nx) and hypoxia 1% O2 (Hx 1%). Each difference in gene
expression was estimated within the limits of a 95% conﬁdence interval. The
results are representative of at least two separate experiments. (C)
Expression of the mRNA of PGM1 was determined by real-time qPCR in
RCC4 (black bars) and 786-O cells (white bars) in the absence (−) or presence
(+) of pVHL expression. Each difference in gene expression was estimated
within the limits of a 95% conﬁdence interval. The results are representative
of at least two separate experiments. (D) Expression of the mRNA of PGM1
in LS174 pTerHIFα cells exposed to 48 h of normoxia (Nx) or hypoxia 1% O2
(Hx 1%) in the absence (−) or presence (+) of Tet (10μg/mL). The level of
PGM1 mRNA was determined by real-time qPCR. Results are representative
of at least two separate experiments with two different primers for PGM1. (E)
CCL39 cells were subjected to normoxia (Nx) or hypoxia 1% O2 (Hx 1%) for 1,
3, 6, 12, and 24 h. Total extracts were analyzed by immunoblotting with
antibodies against HIF-1α, PGM1, and α-tubulin. (F) LS174, MCF-7, and
MDA-MB231 cells were subjected to normoxia (Nx) or hypoxia 1% O2 (Hx
1%) for 48 h. Total extracts were analyzed by immunoblotting with antibodies
against PGM1 and β-Actin. (G) LS174 pTerHIFα cells were exposed for 24 h to
normoxia (Nx) or hypoxia 1% O2 (Hx 1%) in the absence (−) or presence (+)
of Tet (10μg/mL). Total extracts were analyzed by immunoblotting with
antibodies against HIF-1α, PGM1, and ARD-1.
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FIGURE 4 | Glycolysis, respiration, and glycogenesis are closely
connected. (A) CCL39 wild-type (WT), CCL39 respiratory-deﬁcient (Res−),
and CCL39 glycolysis-deﬁcient (Gly−) cell lines derived from wild-type
CCL39 cells were subjected to normoxia (Nx) and hypoxia 1% O2 (Hx 1%)
for 48 h. Total extracts were analyzed by immunoblotting with antibodies
against PGM1 and α-tubulin. (B) Quantiﬁcation of the amount of glycogen
inWT (gray bars), Res− (black bars), and Gly− (white bars) cells grown in
normoxia (Nx) or hypoxia 1% O2 (Hx 1%) for 48 h. (C)WT (), Res− (), and
Gly− () cells were subjected to hypoxia 1% O2 for 96 h and then cultured
in glucose-free medium for up to 8 h. The glycogen concentration was
measured just before removal of glucose and represents 100%.The results
are representative of at least three separate experiments.
Hypoxic CCL39 cells without stored glycogen and in the absence
of glucose died massively (80% cell death) whereas cells with a
high amount of glycogen were able to survive under these con-
ditions (76% cell survival; Figure 5B – left panel). Moreover,
both MCF-7, MDA-MB, and LS174 cells were able to survive
better under drastic conditions when they accumulated glycogen
(Figure 5B – left panel and Figure 5C). In summary, non-cancer
and most cancer cells use glycogen as a source of fuel that can be
mobilized very rapidly to produce energy for survival in a hostile
microenvironment.
DISCUSSION
In this study, we established that almost all the cell lines tested
contain a detectable amount of glycogen, from very low (BE
FIGURE 5 | Glycogen storage protects from cell death. (A) CCL39 (),
LS174 (), MCF-7 (•), and MDA-MB231 (x) cells were subjected to hypoxia
of 1% O2 for 96 h and then cultured in glucose-free medium for up to 6 h.
The glycogen concentration was measured just before removal of glucose
and represents 100%. Glycogen was then measured at 1, 3, and 6 h. The
results are representative of at least three separate experiments. (B)
Measurement of cell death in CCL39 cells. CCL39 (left panel), MCF-7, and
MDA-MB231 (right panel) cells were subjected to either normoxia (−
hypoxic glycogen storage) or hypoxia (+ hypoxic glycogen storage) for 96 h
and incubated in glucose-free medium in hypoxia for 24 h before measuring
cell death. Data represent the average of at least three independent
experiments. (C) Measurement of cell death in LS174 and MDA-MB231
cells in the presence of DAB. Cells were incubated in either normoxia (−
hypoxic glycogen storage) or hypoxia (+ hypoxic glycogen storage) in the
presence of 1,4-dideoxy-1,4-imino-d-arabinitol (DAB) an inhibitor of
glycogen phosphorylase activity. (DAB) for 96 h and incubated in
glucose-free medium in hypoxia for 24 h before measuring cell death. Data
represent the average of at least three independent experiments.
cells) to very high (RCC4 and MCF-7 cells) under normal cell
culture conditions (Table 1; Figure 2). We arbitrarily grouped
these cells into those with the highest (MCF-7 cells) to the lowest
(BE cells) level of glycogen (Table 1). All these cells responded by
an increase in glycogen accumulation when exposed to hypoxia.
However, the previous classiﬁcation totally changes if the cells
are grouped based on the highest level of induction in hypoxia.
CCL39, 786-O, LS174, and BE cells showed the highest differ-
ence between hypoxic and normoxic levels and MCF-7 and RCC4
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cells showed the lowest difference. Only prostate cancer PC3 cells
did not show a difference in the amount of glycogen between
normoxia and hypoxia. Since prostate cancers show a low level
of glucose uptake and a low rate of glycolysis (Liu et al., 2010)
they may rely more on fatty acid metabolism. Alternatively, these
cells might be impaired in glycogen synthesis, a question that
will be addressed in the future with additional prostate cancer
cell lines.
How do cells store glycogen in hypoxia? We demonstrated that
the transcription factor HIF is involved in induction (Figure 2).
Using two different models cell lines, RCC4 (HIF-1 and HIF-
2)± pVHL and LS174 pTerHIF-1 cells, we showed that glycogen
accumulation was dependent on HIF. Our results conﬁrmed pre-
vious results showing that silencing of HIF-1α abrogated glyco-
gen accumulation in mouse myotubes (Pescador et al., 2010)
and in human MCF-7 cells (Shen et al., 2010). However, in the
ﬁrst study, the authors suggested that HIF-2 could contribute
to glycogen accumulation whereas in the second, the authors
showed that silencing of HIF-2α slightly, but not signiﬁcantly,
decreased glycogen storage. Here, we also used renal clear cell
carcinoma 768-O cells that contain only HIF-2α (Figure 2C).
We also examined 786-O cells in which wild-type VHL was
re-introduced. However, 786-O (−pVHL) showed a 40 times
(34.3± 18.5 ng/μg protein) lower glycogen content than RCC4
(+pVHL). In the presence of pVHL, 786-O cells had a lower
glycogen content (1.1± 0.8 ng/μg protein) than in the absence
of pVHL. These results, as suggested by Pescador et al. (2010)
and Shen et al. (2010), indicate that HIF-2α could be involved
but does not predominate. Four new hypoxia-regulated genes
involved in glycogenesis have now been described: muscle glyco-
gen synthase (GYS1), UTP:glucose-1-phosphate uridylyltrans-
ferase (UGP2), 1,4-α glucan branching enzyme (GB1; Pescador
et al., 2010) and protein phosphatase 1, regulatory subunit 3C
(PPP1R3C; Shen et al., 2010). Here, we propose that phos-
phoglucomutase 1 (PGM1), which converts glucose-6-phosphate
into glucose-1-phosphate, is a target for HIF-1 (Figure 3C).
Hypoxia-induced PGM1 expression was observed in all the
cells tested (Figure 3) and correlated with HIF-1α stabilization
(Figure 3D). However, the level of PGM1 expression in nor-
moxia did not correlate with the level of glycogen present in the
cells. For example, normoxic PGM1 expression in MCF-7 cells
was weak compared to normoxic expression of PGM1 in MDA-
MB231 cells (Figure 3E); the amount of glycogen was about
113.9± 5.8 ng/μg protein and 10.0± 2.3 ng/μg protein, respec-
tively (Table 1). Thus most of the genes involved in glycogenesis
seem to be up-regulated by hypoxia suggesting that glycogen
accumulation under hypoxic conditions is an important step in
metabolism.
Why do normal and cancer cells store glycogen? We reported
previously that non-cancer and cancer cells sense hypoxia as the
beginning of a change in the microenvironment (Bellot et al.,
2009). Thus, cells attempt to antagonize these drastic conditions
by creating new survival strategies such as increased glycolysis
or autophagy. Herein we demonstrated that glycogen storage is
a survival process used by cells that sense a forthcoming impov-
erishment in the nutrients of the microenvironment. This is in
agreement with data obtained with mouse neonatal hepatocytes
(Pescador et al., 2010). Glycogenolysis is a fast event as more than
70% of the total glycogen was consumed in only 6 h in all tested
cells. However, the baseline amount of glycogen was different in
different cell lines, MCF-7 cells still had 170 ng/μg protein after
6 h whereas MDA-MB231 had only 30 ng/μg protein (Figure 5A).
Does this make a difference to the survival process? Almost all
the cell lines tested showed improved cell survival in glucose-free
medium after hypoxic preconditioning. As expected CCL39 and
MCF-7 cells, with a high level of glycogen, increased their survival
potential by almost 70 and 50%, respectively. However, MDA-
MB231 cells, with a low level of glycogen and fast consumption of
glycogen were able to survive even better than CCL39 and MCF-7
cells. It is worth noting that MDA-MB231 cells are highly aggres-
sive breast cancer cells compared to the less invasive MCF-7 cells.
LS174 cells, which consumed the total amount of glycogen in 6 h,
did not beneﬁt from their glycogen stores after 24 h (data not
shown).
Taken together, this study showed that non-cancer and cancer
cells could accumulate glycogen in order to adapt and survive in
an oxygen- and glucose-free microenvironment. Thus cells in gen-
eral, and cancer cells in particular, will show an incredible capacity
to adapt and make the most of the harsh conditions to which they
are exposed in assuring tumor progression.
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